Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor

The majority of gastrointestinal stromal tumors (GIST) harbor an activating mutation in either the KIT or PDGFRA receptor tyrosine kinases. Approval of imatinib, a KIT/PDGFRA tyrosine kinase inhibitor (TKI), meaningfully improved the treatment of advanced GIST. Other TKIs subsequently gained approva...

Descripción completa

Detalles Bibliográficos
Autores principales: Bauer, Sebastian, George, Suzanne, von Mehren, Margaret, Heinrich, Michael C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313277/
https://www.ncbi.nlm.nih.gov/pubmed/34322383
http://dx.doi.org/10.3389/fonc.2021.672500

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313277/
https://www.ncbi.nlm.nih.gov/pubmed/34322383
http://dx.doi.org/10.3389/fonc.2021.672500

Ejemplares similares